In a licensing deal unveiled Monday, Lyell Immunopharma is kicking in $40 million in cash and almost 2 million of its shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback